Abstract
This review summarizes the emerging roles of NHERF1/EBP50 adaptor protein in tumorigenesis. NHERF1/EBP50 (Na+/H+ exchanger regulating factor 1; ezrin-radixin-moesin (ERM) binding phosphoprotein of 50 kDa) is a PDZ domain-containing protein with physiological localization at the plasma membrane. We discuss in this review the functions of NHERF1/EBP50 as a linker between membrane proteins and the cytoskeleton network, as well as its involvement in different types of cancer, such as breast and liver cancers. Recent evidence obtained from our laboratory and from other groups shows that NHERF1/EBP50 is an important player in cancer progression. It appears that, depending on its subcellular distribution, NHERF1/EBP50 may behave either as a tumor suppressor, when it is localized at the plasma membrane, or as an oncogenic protein, when it is shifted to the cytoplasm. We provide here an overview of the mechanisms by which this adaptor protein controls cell transformation, and propose a model suggesting a dual role of NHERF1/EBP50 in cancer.
Keywords: NHERF1/EBP50, tumorigenesis, membrane proteins, cytoskeleton, liver cancers, cancer progression, oncogenic protein
Current Molecular Medicine
Title: Roles of NHERF1/EBP50 in Cancer
Volume: 8 Issue: 6
Author(s): Maria-Magdalena Georgescu, Fabiana C. Morales, Jennifer R. Molina and Yuho Hayashi
Affiliation:
Keywords: NHERF1/EBP50, tumorigenesis, membrane proteins, cytoskeleton, liver cancers, cancer progression, oncogenic protein
Abstract: This review summarizes the emerging roles of NHERF1/EBP50 adaptor protein in tumorigenesis. NHERF1/EBP50 (Na+/H+ exchanger regulating factor 1; ezrin-radixin-moesin (ERM) binding phosphoprotein of 50 kDa) is a PDZ domain-containing protein with physiological localization at the plasma membrane. We discuss in this review the functions of NHERF1/EBP50 as a linker between membrane proteins and the cytoskeleton network, as well as its involvement in different types of cancer, such as breast and liver cancers. Recent evidence obtained from our laboratory and from other groups shows that NHERF1/EBP50 is an important player in cancer progression. It appears that, depending on its subcellular distribution, NHERF1/EBP50 may behave either as a tumor suppressor, when it is localized at the plasma membrane, or as an oncogenic protein, when it is shifted to the cytoplasm. We provide here an overview of the mechanisms by which this adaptor protein controls cell transformation, and propose a model suggesting a dual role of NHERF1/EBP50 in cancer.
Export Options
About this article
Cite this article as:
Georgescu Maria-Magdalena, Morales C. Fabiana, Molina R. Jennifer and Hayashi Yuho, Roles of NHERF1/EBP50 in Cancer, Current Molecular Medicine 2008; 8 (6) . https://dx.doi.org/10.2174/156652408785748031
DOI https://dx.doi.org/10.2174/156652408785748031 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Cell Death in the IPLB-LdFB Insect Cell Line: Facts and Implications
Current Pharmaceutical Design Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Zebrafish as a Model for the Study of the Phase II Cytosolic Sulfotransferases
Current Drug Metabolism Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
Current Topics in Medicinal Chemistry Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets An Approach to Treatment of Liver Cancer by Novel Glycyrrhizin Derivative
Anti-Cancer Agents in Medicinal Chemistry The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Computer Aided Drug Design: Success and Limitations
Current Pharmaceutical Design Theranostic Applications of Lutetium-177 in Radionuclide Therapy
Current Radiopharmaceuticals Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications
Current Pharmaceutical Analysis The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies
Current Molecular Medicine Recent Studies on Natural Products as Anticancer Agents
Current Topics in Medicinal Chemistry Perspectives on Sesquiterpene Lactones in Inflammation and Cancer
Current Drug Targets Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets